April 25, 2023
Via: Biopharma DiveThe Food and Drug Administration has conditionally approved a new ALS medicine in a decision likely to influence how other experimental treatments for the nerve-destroying disease are tested and reviewed. The medicine, known until now as tofersen, is only for […]
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
August 30, 2023
September 19, 2023